Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | HTR3A | P46098 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | RBP4 | P02753 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927657 | 0.90 | PARP15 (0.66) | TDP1MAPTPARP15PARP10PARP2 | |
| SCHEMBL7311285 | 0.85 | PARP10 (0.68) | MAPTPARP15PARP10PARP2RAB9A | |
| Trifluoroacetic Acid SCHEMBL31331211 | 0.84 | CHRNB2 (0.52) | TDP1MAPTPARP15PARP10PARP2 | |
| SCHEMBL30198 | 0.84 | PARP15 (0.59) | MAPTPARP15PARP10PARP2RAB9A | |
| SCHEMBL670118 | 0.84 | SLC6A2 (0.52) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL27392262 | 0.84 | TDP1 (0.49) | TDP1PARP15PARP10PARP2SLC6A2 | |
| SCHEMBL4688420 | 0.84 | TDP1 (0.60) | TDP1PARP15PARP10PARP2SLC6A2 | |
| SCHEMBL1963756 | 0.83 | PARP15 (0.57) | TDP1MAPTPARP15PARP10PARP2 | |
| SCHEMBL9577038 | 0.83 | PARP15 (0.57) | MAPTPARP15PARP10PARP2RAB9A | |
| SCHEMBL17078848 | 0.83 | HSP90AA1 (0.48) | TDP1CHEK2RBP4DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115504972-A | Isoxazole derivatives, preparation method thereof and application thereof as medicines | 广东药科大学 | 2022-12-23 | — | — | CN | disclosed |
| CN-108456204-A | Benzothiazine derivative and its preparation method and application | 四川大学 | 2018-08-28 | — | — | CN | disclosed |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | INTERVET INC. | 2014-03-27 | — | — | US | disclosed |
| WO-2012164071-A1 | IMIDAZOLE DERIVATIVES | INTERVET INTERNATIONAL B.V. (NL) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012164071-A1 | IMIDAZOLE DERIVATIVES | INTERVET INTERNATIONAL B.V. (NL) | 2012-12-06 | — | — | WO | disclosed |
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
| US-8053447-B2 | 11β-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2010479-A1 | 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | TDP1 1602/4885MAPT 3783/4885PARP15 2442/4885 |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD17B1 | TDP1 1447/4885MAPT 3649/4885PARP15 2260/4885 |
| US-20140088124-A1 | IMIDAZOLE DERIVATIVES | DGAT1, DGAT2, SOAT1 | TDP1 2407/4885MAPT 2628/4885PARP15 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.